Bortezomib (PS-341)

For research use only. Not for use in humans.

製品コードS1013 別名：Velcade, LDP-341, MLM341, NSC 681239

Bortezomib (PS-341)化学構造

CAS No. 179324-69-7

Bortezomib (PS-341, Velcade, LDP-341, MLM341, NSC 681239) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

サイズ 価格(税別)  
10mM (1mL in DMSO) JPY 17100
JPY 13600
JPY 46800
JPY 113200
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

文献中Selleckの製品使用例(693)

製品安全説明書

Proteasome阻害剤の選択性比較

生物活性

製品説明 Bortezomib (PS-341, Velcade, LDP-341, MLM341, NSC 681239) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
ターゲット
NF-κB [6]
()		 20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
体外試験

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H1838 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrDco57UUN3ME20NVg3NjN{IN88US=> NFvlNGU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
IMR-5 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKwTWM2OD1|NEC5MlYzKM7:TR?= NVfQV5JLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-441-T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTuTWM2OD1{NUKxMlch|ryP NIfSSII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
U-698-M M37LVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVq2WHdiUUN3ME2yNlYzNjF3IN88US=> M1[1fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
COLO-824 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYqzfGdpUUN3ME2xNlYyNjd6IN88US=> NITDWXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
P31-FUJ MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFzMUKuO|Uh|ryP MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KY821 M2fCWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfzXolpUUN3ME2xNFM3NjB2IN88US=> MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RPMI-8866 NF\6PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfGNItKSzVyPUGwNFYvOjhizszN NXv4cZRQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TC-YIK NIPnVGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTd6MT6wNUBvVQ>? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MS-1 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXjTWM2OD15NUmuOFIhdk1? MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
DMS-153 M3\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETjepJKSzVyPUe0Ok45OyCwTR?= M3i5OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SUP-T1 M3rOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH2TWM2OD14OE[uNFQhdk1? NXXBWYg3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SCC-15 M2\pfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTZ4Nz60O{BvVQ>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MSTO-211H M2nQXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke0TWM2OD13N{SuNlYhdk1? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7RWlVKSzVyPUWzNk42PyCwTR?= NF3tVoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
NCI-H889 M1TERWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjDOolKSzVyPUS2NU46OiCwTR?= NIO3eIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
CPC-N Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TmS2lEPTB;NECzMlc4KG6P M3n0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
COLO-668 NHLjS|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfERo1KSzVyPUSwN{42PyCwTR?= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H226 M1n5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Kw[GlEPTB;NECzMlI{KG6P NGfFT4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
TUR NXzkOHRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN7Nj62NUBvVQ>? MoO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
DEL MmTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjHbGl5UUN3ME2zPVEvOjdibl2= NHrZ[nQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
NCI-H1963 NEjWWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLaTWM2OD1|OE[uNVkhdk1? MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
CA46 MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTN5Mz62N{BvVQ>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SNU-C1 M2LReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTN4Mj6wPUBvVQ>? Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
THP-1 NHLWcXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV30WGZpUUN3ME2zNlIvPiCwTR?= M1\hd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SCH MmPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTN{Mj6yNkBvVQ>? MmWwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1522 NWTsUWN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTNyNz6wOUBvVQ>? M1K4W|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LNCaP-Clone-FGC M3;0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJ7NT6yOkBvVQ>? NWPLVJJSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H2171 NGC3U41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTKb5o2UUN3ME2yPFgvQTJibl2= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H187 NVP0OWh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInzO2dKSzVyPUK4O{4xQCCwTR?= NF7TNWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
KASUMI-1 NGXXVlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[xemRyUUN3ME2yPFMvODVibl2= MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-MEL-2 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;McnBKSzVyPUK4NU46KG6P NETHNmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
EW-22 NIjJSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD1{NkOuO|Uhdk1? Mm\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1299 NUDmfmluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L3dGlEPTB;Mk[xMlcyKG6P MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COR-L279 M3[4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIKxNIVKSzVyPUK1Nk4yPyCwTR?= M1GzflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1155 MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjwTG1KSzVyPUKzNE4{OiCwTR?= M3TaclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1395 NWWyTIhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3BNYl2UUN3ME2yNVAvOTNibl2= NWnQWHA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KM-H2 M4DmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrvTWM2OD1zOUeuNFUhdk1? NYHQfFd{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H209 NVXwPItVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDOPXNKSzVyPUG5Ok42OiCwTR?= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H510A M1rIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1zOEWuN|chdk1? MoG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1304 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPZOHZKSzVyPUG2PU4zOSCwTR?= Mn\6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|I2ODRzLze+V2FPT0WUPD;hQi=>
SCLC-21H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF3OT60NUBvVQ>? NGfWSmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK|5USU6JRWK8M4E,
NCI-H524 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37WNWlEPTB;MUW5MlEhdk1? NX\Pd3RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MC116 Mn3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF2OD64OUBvVQ>?